Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 14/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.73 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.73 |
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.68 |
| ▸ | ATG7 | O95352 | 1/20 | 0.68 |
| ▸ | UBA7 | P41226 | 1/20 | 0.68 |
| ▸ | NAE1 | Q13564 | 1/20 | 0.68 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.68 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.68 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.66 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.66 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.66 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.65 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32662178 | 0.93 | ADORA1 (0.85) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL32662091 | 0.92 | ADORA1 (0.84) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL32662392 | 0.92 | ADORA1 (0.84) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL32662022 | 0.92 | ADORA1 (0.84) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL6660596 | 0.87 | ADORA3 (0.86) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 | |
| SCHEMBL6660602 | 0.87 | ADORA3 (0.86) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 | |
| SCHEMBL3716662 | 0.86 | ADORA1 (0.86) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL3716677 | 0.86 | ADORA1 (0.85) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL3716670 | 0.86 | ADORA1 (0.85) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL120566 | 0.85 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015592-A1 | NEDDYLATION-ACTIVATING ENZYME INHIBITORS AS VIRAL SENSITIZERS AND USES THEREOF | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2026-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015592-A1 | NEDDYLATION-ACTIVATING ENZYME INHIBITORS AS VIRAL SENSITIZERS AND USES THEREOF | NAE1, NEDD8, UBA3 | ADORA1 4165/4885ADORA3 4387/4885ADORA2A 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.